Avalo Therapeutics, Inc.
corporate_fare Company Profile
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AVTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for AVTX spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Q3 Loss Narrower Than Expected as Avalo Beats Consensus by $8M
- Avalo Q3 Loss Narrows to $18.9M; $462.8M Cash Funds Operations Into 2029, But Goodwill Impairment Risk Flagged
- Avalo Posts Wider Q2 Loss, Positive Phase 2 Data, and Cash Runway Through 2029
- Avalo Posts $36.4M Q2 Loss, Cash at $472M; Phase 3 for Abdakibart in HS Set for H1 2027
- Avalo Therapeutics Appoints Biotech Veteran Ron Philip to Board of Directors
Financial Snapshot
Short Interest & Short Volume
2.09 days to coverFINRA reported short interest of 8,910,655 shares in AVTX as of the October 30, 2026 settlement, a 25.5% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 36.6% of AVTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AVTX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.
New $200M ATM With Jefferies · Jefferies Takes Up to 3.0%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →